New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 18, 2014
08:37 EDTBAYRY, OMEDOncoMed begins second Phase 1b clinical trial for OMP-54F28 with sorafenib
OncoMed Pharmaceuticals (OMED) announced that it has started a multi-center Phase 1b clinical trial of OMP-54F28 with sorafenib in hepatocellular cancer, or HCC. OMP-54F28 is a first-in-class Wnt-pathway-targeting decoy receptor and is part of OncoMed's collaboration with Bayer Pharma AG (BAYRY). This is the second of three Phase 1b trials for OMP-54F28 to begin patient enrollment; earlier this year OncoMed initiated a Phase 1b of OMP-54F28 with nab-paclitaxel and gemcitabine in pancreatic cancer. The Phase 1b clinical trial is a dose-escalation study of OMP-54F28 in combination with sorafenib in patients with first-line locally advanced or metastatic HCC. Primary objectives of the trial are to evaluate safety of this combination regimen and determine a recommended Phase 2 dose for OMP-54F28 in combination with sorafenib. Key secondary and exploratory objectives include evaluation of the pharmacokinetics and pharmacodynamics of OMP-54F28, as well as the efficacy of this combination. Tumor tissue from patients will be used to explore predictive biomarker hypotheses related to the efficacy of OMP-54F28.
News For OMED;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
11:40 EDTBAYRYBayer sees stock market flotation for MaterialScience unit by mid-2016 at latest
Subscribe for More Information
10:03 EDTBAYRYBayer announces capacity expansion at facilities producing weed control system
Subscribe for More Information
August 31, 2015
08:40 EDTOMEDOncoMed completes enrollment of tarextumab Phase 2 ALPINE clinical trial
Subscribe for More Information
August 25, 2015
10:14 EDTBAYRYForward signs supplier agreement extension with Bayer Healthcare
Subscribe for More Information
August 20, 2015
05:48 EDTOMEDMizuho keeps TESARO, Verastem, OncoMed as top biotech picks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use